{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:41:21Z","timestamp":1791157281449,"version":"4.1.0"},"reference-count":74,"publisher":"Informa UK Limited","issue":"3","funder":[{"name":"Argos Therapeutics, Novartis, Bristol Myers Squibb, Immatics and Exilexis"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Immunotherapy"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.2217\/imt.13.168","type":"journal-article","created":{"date-parts":[[2013,12,19]],"date-time":"2013-12-19T15:56:56Z","timestamp":1387468616000},"page":"261-268","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":7,"title":["A Novel Personalized Vaccine Approach in Combination with Targeted Therapy in Advanced Renal Cell Carcinoma"],"prefix":"10.1080","volume":"6","author":[{"given":"Robert A","family":"Figlin","sequence":"first","affiliation":[{"name":"Samuel Oschin Comprehensive Cancer Institute,Cedars-Sinai Medical Center,\r8700 Beverly Boulevard, Saperstein Critical Care Tower 1S28,\rLos Angeles,\rCA,\r90048,\rUSA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2014,4,24]]},"reference":[{"key":"e_1_3_2_3_1","volume-title":"Cancer Facts & Figures 2013","year":"2013","unstructured":"Cancer Facts & Figures 2013. American Cancer Society, GA, USA (2013)."},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00041552-200201000-00006"},{"key":"e_1_3_2_5_1","first-page":"1","volume-title":"NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. v1.2013.","year":"2013","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Kidney Cancer. v1.2013. National Comprehensive Cancer Network, PA, USA, 1\u201324 (2013)."},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198704093161501"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.1.289"},{"issue":"1","key":"e_1_3_2_8_1","first-page":"206","article-title":"Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity","volume":"48","author":"Belldegrun A","year":"1988","unstructured":"Belldegrun A, Muul LM, Rosenberg SA. Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res. 48(1), 206\u2013214 (1988).","journal-title":"Cancer Res."},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19960927)68:1<1::AID-IJC1>3.0.CO;2-V"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2011.0085"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.688"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-008-9148-x"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066838"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065044"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24236"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-S2-14"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2010.57"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24227"},{"issue":"5","key":"e_1_3_2_19_1","first-page":"307","article-title":"Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma","volume":"10","author":"Carmichael C","year":"2012","unstructured":"Carmichael C, Lau C, Josephson DY, Pal SK. Comprehensive overview of axitinib development in solid malignancies: focus on metastatic renal cell carcinoma. Clin. Adv. Hematol. Oncol. 10(5), 307\u2013314 (2012).","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.2165\/11591240-000000000-00000"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25327"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.6_suppl.lba348"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.1293"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.9764"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303989"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61904-7"},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.5561"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.2147\/BTT.S32958"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.4940"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2011.04.008"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2011.12.009"},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7609"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.7_suppl.331"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds264"},{"issue":"12","key":"e_1_3_2_35_1","first-page":"1319","article-title":"TG-4010 transgene","volume":"5","author":"Cohen S","year":"2004","unstructured":"Cohen S, Kaufman HL. TG-4010 transgene. Curr. Opin. Investig. Drugs 5(12), 1319\u20131328 (2004).","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4905"},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/jgm.397"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-010-0935-9"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1990.20"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2082"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712590903085109"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2883"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.4161\/onci.22246"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1586\/erv.13.22"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.2003.tb06047.x"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri2173"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/624123"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0018801"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.5_suppl.348"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.6_suppl.357"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2013.18"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0001489"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318183db02"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2079"},{"key":"e_1_3_2_56_1","first-page":"165","article-title":"Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells.","volume":"27","author":"Porta C","year":"2007","unstructured":"Porta C, Bonomi L, Lillaz B et al. Renal cell carcinoma-induced immunosuppression: an immunophenotypic study of lymphocyte subpopulations and circulating dendritic cells. Anticancer Res. 27(1A), 165\u2013173 (2007).","journal-title":"Anticancer Res."},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1462399402004283"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e3181fb651a"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.6147"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-4323"},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26219"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25863"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1590\/S1677-55382011000200004"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-5212"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.2532"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-02-075945"},{"key":"e_1_3_2_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70241-3"},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61039-9"},{"key":"e_1_3_2_69_1","article-title":"Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).","volume":"30","author":"Choueiri TK","year":"2012","unstructured":"Choueiri TK, Pal SK, McDermott DF et al. Efficacy of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC). J. Clin. Oncol. 30(Suppl.), Abstract 4504 (2012).","journal-title":"J. Clin. Oncol."},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.4551"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.31.6_suppl.418"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2011.07.018"},{"key":"e_1_3_2_73_1","unstructured":"A Phase 2 randomized double-blind crossover controlled multi-center subject preference study of tivozanib hydrochloride versus sunitinib in the treatment of subjects with metastatic renal cell carcinoma. http:\/\/clinicaltrials.gov\/show\/NCT01673386"},{"key":"e_1_3_2_74_1","unstructured":"A Phase IIB\/III randomized double-blind placebo controlled study comparing first line therapy with or without TG4010 immunotherapy product in patients with stage IV non-small cell lung cancer (NSCLC). http:\/\/clinicaltrials.gov\/show\/NCT01383148"},{"key":"e_1_3_2_75_1","unstructured":"A randomized controlled Phase III study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced\/metastatic renal cell carcinoma. http:\/\/clinicaltrials.gov\/show\/NCT01265901"},{"key":"e_1_3_2_76_1","unstructured":"An international Phase 3 randomized trial of autologous dendritic cell immunotherapy (AGS-003) plus standard treatment of advanced renal cell carcinoma (ADAPT). http:\/\/clinicaltrials.gov\/show\/NCT01582672"}],"container-title":["Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/imt.13.168","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T11:00:59Z","timestamp":1715943659000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/imt.13.168"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":74,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.2217\/imt.13.168"],"URL":"https:\/\/doi.org\/10.2217\/imt.13.168","relation":{},"ISSN":["1750-743X","1750-7448"],"issn-type":[{"value":"1750-743X","type":"print"},{"value":"1750-7448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iimy20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2014-04-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}